Chronic toxicity and long-term outcome in intraoperative electron radiotherapy as boost followed by whole-breast irradiation.
Adult
Aged
Aged, 80 and over
Breast
/ radiation effects
Breast Neoplasms
/ mortality
Carcinoma, Ductal, Breast
/ mortality
Electrons
/ therapeutic use
Female
Fibrosis
/ pathology
Humans
Intraoperative Period
Mastectomy, Segmental
Middle Aged
Neoplasm Recurrence, Local
/ prevention & control
Postoperative Complications
Prospective Studies
Radiation Injuries
/ pathology
Radiotherapy Dosage
Treatment Outcome
Boost radiotherapy
Breast cancer
Chronic toxicity
IOERT
Intraoperative electron radiotherapy
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
06
12
2020
accepted:
12
01
2021
pubmed:
4
2
2021
medline:
1
12
2021
entrez:
3
2
2021
Statut:
ppublish
Résumé
The administration of a dose boost to the tumor bed after breast-conserving surgery has proven to reduce local recurrence. Intra-operative electron radiotherapy (IOERT) offers an alternative method to deliver a boost with several advantages, such as direct visualization of the tumor bed, less inter- and intrafraction motion and a reduction in the number of medical appointments. The objective of our study is to assess chronic toxicity and long-term outcome for our patients after IOERT boost. Forty-six patients treated at our institution between July 2013 and June 2020 with IOERT boost during Breast-Conserving Surgery and consecutive whole breast irradiation were prospectively analyzed. A 10-12 Gy boost was prescribed to 42 patients and 4 patients received a 20 Gy boost. An analysis for overall survival, local relapse and distant progression was performed. Acute and chronic toxicity was assessed by CTCAE 4.0. The median age was 64.5 years (40-90). The median follow-up was 62 months (4-86). We had no local recurrences but 2 patients (4.3%) presented a distant recurrence. Mean pathological tumor size was 16 mm (6-52). 84.8% (39) of the patients had invasive ductal carcinoma. 52.2% (24) presented histological grade II. 52.2% (24) were Luminal A like, 21.7% (10) Luminal B like, 13% (6) HER2 positive, 13% (6) triple negative. No Grade 3-4 chronic toxicity was observed. Grade 1-2 fibrosis was evidenced in 13% (6) of the patients, 4.3% (2) patients presented fat necrosis, 6.5% (3) presented seroma, 4.3% (2) had localized pain, 2.2% (1) presented localized hematoma and 2.2% (1) presented localized edema. IOERT boost in breast cancer treatment during BCS is a safe option with low chronic toxicity. The recurrence rates are comparable to published data and emphasize that IOERT as boost is an effective treatment.
Identifiants
pubmed: 33534078
doi: 10.1007/s12094-021-02555-3
pii: 10.1007/s12094-021-02555-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1593-1600Références
Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16. https://doi.org/10.1016/S0140-6736(11)61629-2 .
doi: 10.1016/S0140-6736(11)61629-2
pubmed: 22019144
Kuerer HM, Julian TB, Strom EA, Lyerly HK, Giuliano AE, Mamounas EP, et al. Accelerated partial breast irradiation after conservative surgery for breast cancer. Ann Surg. 2004;239(3):338e51. https://doi.org/10.1097/01.sla.0000114219.71899.13 .
doi: 10.1097/01.sla.0000114219.71899.13
Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881–10882 trial. J Clin Oncol. 2007;25:3259e65. https://doi.org/10.1200/JCO.2007.11.4991 .
doi: 10.1200/JCO.2007.11.4991
Poortmans P, Bartelink H, Horiot JC, Struikmans H, Van den Bogaert W, Fourquet A, et al. The influence of the boost technique on local control in breast conserving treatment in the EORTC ‘boost versus no boost’ randomised trial. Radiother Oncol. 2004;72:25e33. https://doi.org/10.1016/j.radonc.2004.03.007 .
doi: 10.1016/j.radonc.2004.03.007
Perez CA, Taylor ME, Halverson K, Garcia D, Kuske RR, Lockett MA. Brachytherapy or electron beam boost in conservation therapy of carcinoma of the breast: a nonrandomized comparison. Int J Radiat Oncol Biol Phys. 1996;34:995e1007. https://doi.org/10.1016/j.rpor.2010.01.002 .
doi: 10.1016/j.rpor.2010.01.002
Hill-Kayser CE, Chacko D, Hwang WT, Vapiwala N, Solin LJ. Long-term clinical and cosmetic outcomes after breast conservation treatment for women with early-stage breast carcinoma according to the type of breast boost. Int J Radiat Oncol Biol Phys. 2011;79:1048e54. https://doi.org/10.1016/j.ijrobp.2009.12.026 .
doi: 10.1016/j.ijrobp.2009.12.026
Wazer DE, Kramer B, Schmid C, Ruthazer R, Ulin K, Schmidt-Ullrich R. Factors determining outcome in patients treated with interstitial implantation as a radiation boost for breast conservation therapy. Int J Radiat Oncol Biol Phys. 1997;39:381e93. https://doi.org/10.1016/S0360-3016(97)00325-8 .
doi: 10.1016/S0360-3016(97)00325-8
Mansfield CM, Komarnicky LT, Schwartz GF, Rosenberg AL, Krishnan L, Jewell WR, et al. Ten-year results in 1070 patients with stages I and II breast cancer treated by conservative surgery and radiation therapy. Cancer. 1995;75:2328e36. https://doi.org/10.1002/1097-0142 (AID-CNCR2820750923>3.0.CO;2-L).
doi: 10.1002/1097-0142
Touboul E, Belkacemi Y, Lefranc JP, Uzan S, Ozsahin M, Korbas D, et al. Early breast cancer: influence of type of boost (electrons vs iridium-192 implant) on local control and cosmesis after conservative surgery and radiation therapy. Radiother Oncol. 1995;34:105e13. https://doi.org/10.1016/0167-8140(95)01508-e .
doi: 10.1016/0167-8140(95)01508-e
Antonini N, Jones H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881–10882. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2007;82:265–71. https://doi.org/10.1016/j.radonc.2006.09.014 .
doi: 10.1016/j.radonc.2006.09.014
Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16:47–56. https://doi.org/10.1016/S1470-2045(14)71156-8 .
doi: 10.1016/S1470-2045(14)71156-8
pubmed: 25500422
Romestaing P, Lehingue Y, Carrie C, Coquard R, Montbarbon X, Ardiet JM, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon. France J Clin Oncol. 1997;15:963–8. https://doi.org/10.1200/JCO.1997.15.3.963 .
doi: 10.1200/JCO.1997.15.3.963
pubmed: 9060534
Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30:1541–57. https://doi.org/10.1093/annonc/mdz235 .
doi: 10.1093/annonc/mdz235
pubmed: 31373601
Fastner G, Sedlmayer F, Merz F, Deutschmann H, Reitsamer R, Menzel C, et al. IORT with electrons as boost strategy during breast conserving therapy in limited stage breast cancer: long term results of an ISIORT pooled analysis. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2013;108:279–86. https://doi.org/10.1016/j.radonc.2013.05.031 .
doi: 10.1016/j.radonc.2013.05.031
Kaiser J, Kronberger C, Moder A, Kopp P, Wallner M, Reitsamer R, et al. Intraoperative tumor bed boost with electrons in breast cancer of clinical stages I through III: updated 10-year results. Int J Radiat Oncol Biol Phys. 2018;102:92–101. https://doi.org/10.1016/j.ijrobp.2018.05.028 .
doi: 10.1016/j.ijrobp.2018.05.028
pubmed: 29970317
Fastner G, Reitsamer R, Ziegler I, Zehentmayr F, Fussl C, Kopp P, et al. IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer–results of a case series after 5-year follow-up. Int J Cancer. 2015;136:1193–201. https://doi.org/10.1002/ijc.29064 .
doi: 10.1002/ijc.29064
pubmed: 24995409
Fastner G, Hauser-Kronberger C, Moder A, Reitsamer R, Zehentmayr F, Kopp P, et al. Survival and local control rates of triple-negative breast cancer patients treated with boost-IOERT during breast-conserving surgery. Strahlenther Onkol. 2016;192:1–7. https://doi.org/10.1007/s00066-015-0895-2 .
doi: 10.1007/s00066-015-0895-2
pubmed: 26403912
Shah C, Al-Hilli Z, Schwarz G, et al. Oncoplastic surgery in breast cancer: don’t forget the boost! Ann Surg Oncol. 2018;25:2509–11. https://doi.org/10.1245/s10434-018-6571-x .
doi: 10.1245/s10434-018-6571-x
pubmed: 29905890
Tom MC, Joshi N, Vicini F, Chang AJ, Hong TS, Showalter TN, et al. The American Brachytherapy Society consensus statement on intraoperative radiation therapy. Brachytherapy. 2019. https://doi.org/10.1016/j.brachy.2019.01.015 .
doi: 10.1016/j.brachy.2019.01.015
pubmed: 31813740
Fastner G, Reitsamer R, Urbanski B, Kopp P, Murawa D, Adamczyk B, et al. Toxicity and cosmetic outcome after hypofractionated whole breast irradiation and boost-IOERT in early stage breast cancer (HIOB): first results of a prospective multicenter trial (NCT01343459). Radiother Oncol. 2020;146:136142. https://doi.org/10.1016/j.radonc.2020.02.001 .
doi: 10.1016/j.radonc.2020.02.001
Fastner G, Gaisberger C, Kaiser J, Scherer P, Ciabattoni A, Petoukhova A, et al. Guidelines ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy with electrons (IOERT) in breast cancer. Radiother Oncol. 2020;149:150–7. https://doi.org/10.1016/j.radonc.2020.04.059 .
doi: 10.1016/j.radonc.2020.04.059
pubmed: 32413529
Haviland JS, Owen JR, Dewar JA, Agrawal R, Barrett J, Barrett-Lee P, et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086–94. https://doi.org/10.1016/S1470-2045(13)70386-3 .
doi: 10.1016/S1470-2045(13)70386-3
pubmed: 24055415
Whelan TJ, Pignol JP, Levine MN, Julian JA, Mackenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–20. https://doi.org/10.1056/NEJMoa0906260 .
doi: 10.1056/NEJMoa0906260
pubmed: 20147717
Ivaldi G, Leonardi C, Orecchia R, Zerini D, Morra A, Galimberti V, et al. Preliminary results of electron intraoperative therapy boost and hypofractionated external beam radiotherapy after breast-conserving surgery in premenopausal women. Int J Radiat Oncol Biol Phys. 2008;72:485–93. https://doi.org/10.1016/j.ijrobp.2007.12.038 .
doi: 10.1016/j.ijrobp.2007.12.038
pubmed: 18407434
Köning L, Lang K, Heil J, Golatta M, Major G, Krung D, et al. Acute toxicity and early oncological outcomes after intraoperative electron radiotherapy (IOERT) as boost followed by whole breast irradiation in 157 early stage breast cancer patients first clinical results from a single center. Front Oncol. 2019;9:384. https://doi.org/10.3389/fonc.2019.00384 .
doi: 10.3389/fonc.2019.00384
Oses G, Barreto TD, Cases C, Castro C, Lloret A, Saez J, Mollà M. PB-087 Hypofractioned boost to the tumor bed in early breast cancer: Skin toxicity analysis. Poster accepted in European Breast Cancer Conference (EBCC12).